PURPOSE Total neoadjuvant therapy is a new paradigm for rectal cancer treatment. Optimal
scheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be …

Background Neoadjuvant chemoradiotherapy (nCRT) before total mesorectal excision
(TME) and followed systemic chemotherapy is widely accepted as the standard therapy for …

Cancer is one of the leading causes of death with a mortality rate of 12%. Although
significant progress has been achieved in cancer research, the effective treatment of cancer …

Tumour hypoxia contributes to poor treatment outcome in locally advanced rectal cancer
(LARC) and circulating extracellular vesicles (EVs) as potential biomarkers of tumour …

Background Recent data have demonstrated that in locally advanced rectal cancer (LARC),
a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and …

Numerous studies have reported that lncRNAs could play a significant role in
carcinogenesis. PART1, as an identified lncRNA, was an oncogene in several cancers …

Neoadjuvant chemoradiation (NCRT) followed by total mesorectal excision is the standard
treatment for locally advanced rectal cancer (LARC). To justify a non-surgical approach …

Objective: This systematic review and meta-analysis seeks to evaluate the impact of total
neoadjuvant therapy (TNT) for rectal cancers on surgical complications and surgical …

Locally advanced rectal cancer requires multidisciplinary care. In the United States, most
patients are treated with neoadjuvant chemoradiation delivered over 25‐28 days, total …

Cisplatin resistance is the main cause of colorectal cancer (CRC) treatment failure, and the
cause has been reported to be related to Fusobacterium nucleatum (Fn) infection. In this …